Champions Oncology Inc
NASDAQ:CSBR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Champions Oncology Inc
Gross Profit
Champions Oncology Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Champions Oncology Inc
NASDAQ:CSBR
|
Gross Profit
$26.6m
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
24%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Gross Profit
$18.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
9%
|
|
|
Danaher Corp
NYSE:DHR
|
Gross Profit
$14.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
Waters Corp
NYSE:WAT
|
Gross Profit
$1.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Gross Profit
$3.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Gross Profit
$5.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
Champions Oncology Inc
Glance View
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Baltimore, Maryland and currently employs 194 full-time employees. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
See Also
What is Champions Oncology Inc's Gross Profit?
Gross Profit
26.6m
USD
Based on the financial report for Jan 31, 2026, Champions Oncology Inc's Gross Profit amounts to 26.6m USD.
What is Champions Oncology Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
24%
Over the last year, the Gross Profit growth was -12%. The average annual Gross Profit growth rates for Champions Oncology Inc have been 2% over the past three years , 7% over the past five years , and 24% over the past ten years .
